Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Ercolani

Urology Venice, FL Medical Doctor

NPI 1801059894 CMS profile 81598

401 Commercial Ct Ste E, Venice, FL 34292

Open in the dashboard

General payments

$415,817

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Ercolani of Venice, FL is reported in the CMS Open Payments database as having received $415,817 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $777 11
2024 General $1,112 19
2023 General $1,204 15
2022 General $452 8
2021 General $1,444 18
2020 General $51,498 41
2019 General $359,330 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Ercolani
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Matthew Ercolani were reported at $777. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Matthew Ercolani Urology median Middle half National median
2019 $359,330 $480 $147–$1,201 $163
2020 $51,498 $246 $87–$645 $114
2021 $1,444 $358 $111–$1,000 $132
2022 $452 $476 $143–$1,263 $149
2023 $1,204 $560 $168–$1,461 $160
2024 $1,112 $563 $170–$1,464 $164
2025 $777 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $252,191 14 payments
  2. Uromedica, Incorporated $98,157 17 payments
  3. NeoTract Inc. $42,392 55 payments
  4. Intuitive Surgical, Inc. $17,753 26 payments
  5. Axonics Modulation Technologies, Inc. $1,924 34 payments
  6. Medtronic USA, Inc. $788 21 payments
  7. PROCEPT BioRobotics Corporation $497 5 payments
  8. KARL STORZ Endoscopy-America $416 6 payments
  9. Boston Scientific Corporation $311 8 payments
  10. Teleflex LLC $224 2 payments
  11. Other $1,164 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $270,704 16 payments
  2. Honoraria $98,000 2 payments
  3. Consulting Fee $13,244 4 payments
  4. Travel and Lodging $12,043 39 payments
  5. Education $12,000 3 payments
  6. Food and Beverage $9,826 145 payments
Products named General payments · program years 2019–2025
  1. ProACT $98,157 17 payments
  2. UROLIFT $42,392 55 payments
  3. Da Vinci Surgical System $17,753 26 payments
  4. Monarch Platform $8,502 5 payments
  5. Axonics $1,898 33 payments
  6. INTERSTIM $788 21 payments
  7. AQUABEAM SYSTEM $321 3 payments
  8. UroLift System $224 2 payments
  9. Bulkamid $217 4 payments
  10. AQUABEAM ROBOTIC SYSTEM $176 2 payments
  11. Other $1,113 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

400

Median for Urology: 1,053

Drug cost

$14,602

Median for Urology: $101,464

Branded share of claims

8.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 11 $6,842
Tolterodine Tartrate Generic 54 $4,957
Tamsulosin Hcl Generic 90 $991
Bethanechol Chloride Generic 11 $547
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 12 $428
Cephalexin Generic 81 $248
Oxybutynin Chloride Er Oxybutynin Chloride Brand 11 $232
Oxybutynin Chloride Generic 16 $139
Tramadol Hcl Generic 69 $93
Ciprofloxacin Hcl Generic 27 $78

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$136,474

Medicare's payments for the services billed

Medicare patients

508

Average age 73

Services billed

1,337

234 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 38%
COPD 30%
Ischemic heart disease 29%
Chronic kidney disease 27%
Cancer 23%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record